Vaccines and Related Biological Products Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments—Safety and Effectiveness of MFLUSIVA (Influenza Vaccine, mRNA) Manufactured by Moderna TX Inc.

An individual is writing to express support for the approval of Moderna's mRNA influenza vaccine. They argue that the vaccine is an improvement that allows for more timely updates to match circulating strains.

A registered nurse and participant in the Moderna mRNA flu vaccine phase 3 trial supports the approval of the vaccine. The commenter emphasizes the need for more flu vaccine options and praises the quality of the trial.

The commenter supports the approval of Moderna's mRNA influenza vaccine, arguing that the platform allows for more timely updates and better protection against emerging pathogens. They urge the FDA to proceed with the review based on scientific evidence rather than external interference.

The commenter supports the development and use of mRNA influenza vaccines, specifically highlighting Moderna's mRNA-1010. They argue that mRNA technology allows for faster production and better antigenic matches, which are crucial for protecting high-risk populations like older adults.

A private citizen expresses support for the availability of the Moderna mRNA flu vaccine. She argues that mRNA technology provides more flexible and rapid protection against evolving flu strains.

Stephanie Keim supports the approval of Moderna's mRNA flu vaccine, citing its superior efficacy and faster production capabilities compared to traditional egg-based vaccines. She argues that vaccine approvals should be based on scientific evidence and proceed without unnecessary delay.

A healthcare professional at a Midwestern university supports the review of the mRNA influenza vaccine, emphasizing the need for improved options for older and immunocompromised adults. The commenter stresses the importance of scientific rigor and data-driven decision-making in the approval process.

An individual is writing to express strong support for the review and approval of Moderna's mRNA influenza vaccine. The commenter argues that the mRNA platform offers superior effectiveness and flexibility for matching circulating strains compared to standard vaccines.